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Abstract
The mitogen-activated protein kinases (MAPK) ERK1 and ERK2 are among the major signal transduction molecules but little
is known about their specific functions in vivo. ERK activity is provided by two isoforms, ERK1 and ERK2, which are
ubiquitously expressed and share activators and substrates. However, there are not in vivo studies which have reported a
role for ERK1 or ERK2 in HSCs and the bone marrow microenvironment. The present study shows that the ERK1-deficient
mice present a mild osteopetrosis phenotype. The lodging and the homing abilities of the ERK1
2/2 HSC are impaired,
suggesting that the ERK1
2/2-defective environment may affect the engrafment of HSCs. Serial transplantations
demonstrate that ERK1 is involved in the maintenance of an appropriate medullar microenvironment, but that the
intrinsic properties of HSCs are not altered by the ERK1
2/2 defective microenvironment. Deletion of ERK1 impaired in vitro
and in vivo osteoclastogenesis while osteoblasts were unaffected. As osteoclasts derive from precursors of the monocyte/
macrophage lineage, investigation of the monocytic compartment was performed. In vivo analysis of the myeloid lineage
progenitors revealed that the frequency of CMPs increased by approximately 1.3-fold, while the frequency of GMPs
significantly decreased by almost 2-fold, compared with the respective WT compartments. The overall mononuclear-
phagocyte lineage development was compromised in these mice due to a reduced expression of the M-CSF receptor on
myeloid progenitors. These results show that the cellular targets of ERK1 are M-CSFR-responsive cells, upstream to
osteoclasts. While ERK1 is well known to be activated by M-CSF, the present results are the first to point out an ERK1-
dependent M-CSFR regulation on hematopoietic progenitors. This study reinforces the hypothesis of an active cross-talk
between HSCs, their progeny and bone cells in the maintenance of the homeostasis of these compartments.
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Introduction
Adult hematopoietic stem cells (HSCs) exist in a relatively
quiescent state in the bone marrow (BM) microenvironment to
execute long-term self renewal and multilineage differentiation
functions [1,2]. The maintenance of HSC quiescence involves
both intrinsic and extrinsic mechanisms. HSCs interact with the
BM microenvironment in specific anatomical and functional
areas, referred as niches, a microenvironment of different cell types
and extracellular matrix molecules that dictate stem cell self-
renewal and progeny production in vivo [3]. Many studies have
begun to define the medullar niche but few data are available
concerning the cells and factors supporting HSCs in those niches.
Likewise, the signaling pathways governing activation of various
stromal cells and the specific relationship between this activation
state and expansion/maintenance of HSCs are largely unexplored.
HSCs reside in medullar niches, mainly localized in the
endosteum. The so-called endosteal stem cell niche is a
dynamically remodeled tissue that allows interactions between
stem cells and their partners, including osteoblasts and stromal
cells, which provide HSCs with signals for their homeostatic
quiescent state [4,5,6,7]. The architecture of the HSC niche is
tightly controlled by a balance between the bone-forming cells
(osteoblasts), and the bone-resorbing cells (osteoclasts) [8].
While osteoblasts derive from mesenchymal cells, osteoclasts
derive from mononuclear precursors of the monocytic/macro-
phage lineage [9]. Monocytes develop from hematopoietic stem
cells in the bone marrow through several intermediate progenitors
that restrict progressively their differentiation potential [10]. The
prevalent model for myeloid commitment implicates that progen-
itors pass through the common myeloid progenitor (CMP), the
granulocyte/macrophage progenitor (GMP), and the macro-
phage/dendritic cell progenitors (MDP) stages [11]. Each of these
steps is tightly regulated by the interplay between cytokine-induced
signaling pathway and transcription factor activity. Monocyte-
colony stimulating factor (M-CSF), through its binding to M-
CSFR (CD115, Csf1-R) [12] plays an essential role in both
proliferation and differentiation of the myeloid progenitors. M-
CSF, and receptor activator of nuclear factor kappa B ligand
(RANKL), are essential for osteoclastogenesis [9,13,14,15,16].
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results in a lack of osteoclast differentiation and consequent defects
in BM cavity formation, a condition termed osteopetrosis in which
BM cavities are filled with bone [17,18,19]. Accumulating
evidence suggests that osteoclasts induce hematopoietic activity
by secreting bone-resorbing enzymes which promote the mobili-
zation of HSCs from their quiescent state [7]. However, the
influence of HSCs on their microenvironment is not well
understood. A recent report demonstrated a cross-talk between
HSCs and bone cells in the maintenance of both hematopoietic
and bone homeostasis [20].
The ERK MAPK kinases are major signaling actors relaying
signals elicited by cytokines, morphogens or integrins. The MAPK
pathway exerts pleiotropic effects on cell cycle, apoptosis and
differentiation, and has been implicated in the control of many
cellular responses. ERK activity is provided by two isoforms,
named ERK1 and ERK2, that are highly similar, ubiquitously
expressed and that share activators and substrates. We and others
have found that the ERK pathway is specifically required for the
differentiation of various hematopoietic lineages [21,22,23,24].
However, no studies have reported the role of ERK1 or ERK2 in
HSCs in vivo. Gene disruption has suggested specific functions for
each isoform. Ablation of ERK2 induces embryonic lethality with
death of the animals in utero at day 7.5, due to defects in the
mesoderm and placental development [25]. Conversely, ERK1
2/
2 mice are viable, fertile and present minor defects, showing that
ERK1 is dispensable for mouse development and could be
compensated by ERK2. So far, ERK1 has been shown to be
specifically required for in vitro and in vivo adipogenesis, terminal
differentiation of T lymphocytes, long-term memory and erythro-
poiesis [26,27,28,29].
The involvement of the MAPK pathway in myeloid maturation
has been implicated in several myeloid cell lines [30]. Using ERK
chemical inhibitors, Hsu et al. have shown that ERK signaling is
involved in the early myeloid commitment of HSCs [31]. On the
other hand, ERK inhibitors have been reported to alter osteoclast
differentiation and function [32]. Very recently, He Y et al.
reported the preponderant role of ERK1 over ERK2 isoform in
controlling osteoclast differentiation and bone resorption activity
[33]. This suggests that ERKs might have a role in stem cell niche
regulation. However, this possibility together with the precise role
of the ERK pathway in the regulation of myelopoieseis in vivo,t o
our knowledge, has not been reported.
We show here that ERK1-deficient mice present an alteration
of bone density due to impaired osteoclastogenesis. In addition to
osteoclasts, the overall mononuclear-phagocyte lineage develop-
ment was compromised in these mice due to a reduced expression
of the M-CSF receptor on myeloid progenitors. Although resting
medullar hematopoiesis is normal in the absence of ERK1 [29],
serial transplantation experiments revealed that ERK1 deficiency
in the microenvironment alters the lodging and the functional
activity of normal HSCs. Thus, our findings extend the role of
ERK1 in vivo, through regulation of M-CSFR, as a key participant
in the regulation of the niche size.
Methods
Mice
ERK1
2/2 mice, backcrossed on C57BL/6 (CD45.2) back-
ground, and WT C57BL/6J (CD45.2 and CD45.1) mice (Charles
River Laboratories,L’arbresle, France) were housed in a specific
pathogen-free environment. All procedures were approved by the
Animal Care Committee (registred no. P2.MG.137.10, 2010).
Animal studies described herein were reviewed and approved
(agreement no. 75-1064) by the Departmental director of
veterinary services of Paris, France.
Flow cytometry
For analysis of HSCs, BM cells were first stained with
biotinylated-lineage cocktail antibodies (BD Biosciences) with
additional biotinylated antibody specific for CD4, CD8, CD19
and NK1.1 (BioLegend), followed by streptavidin-PerCP second-
ary antibody (BioLegend) and PE-Cy7-conjugated anti-Sca1
(BioLegend), APC-eFluor780-conjugated anti-c-Kit (eBioscience),
PE-conjugated anti-CD150 (BioLegend), Pacific Blue-conjugate
anti-CD48 (BioLegend), APC-conjugated anti-CD135 (BD Phar-
mingen) and FITC-conjugated anti-CD34 (eBioscience). To
analyze mature lineage cells, freshly isolated BM were immuno-
stained with antibodies for myeloid cells (PE-conjugated anti-
CD11b, FITC-conjugated anti-Gr1), B-cells (PE-conjugated anti-
B220), T-cells (PE-conjugated anti-CD4, FITC-conjugated anti-
CD8) (Biolegend). For analysis of BM monocytes and macro-
phages (MW), cells were preincubated with Fc blocking treatment,
and subsequently stained with PE-conjugated anti-Gr1, APC-
conjugated anti-CD115, and pacific blue-conjugated anti-F4/80
(MW). For phenotypic analysis of myeloid progenitors (CMP,
GMP, MEP), cells were stained with the following biotinylated-
lineage antibodies B220, CD11b, Gr1, Ter119, CD3e and Il-7Ra
(eBioscience, San Diego, CA). Lineage-positive cells were removed
with BD IMag streptavidin particles (BD) and the remaining cells
were stained with streptavidin-APC. Cells were incubated with
PE/CY7-conjugated anti-Sca-1, PE-conjugated anti-c-Kit, APC-
CY7-conjugated anti-FccRII/III, and FITC-conjugated anti-
CD34. The common myeloid progenitors (CMPs) were defined
as Lin
2Sca-1
2IL7R
2c-Kit
+CD34
+FccRII/III
lo, the granulo-mac-
rophage progenitors (GMPs) cells as Lin
2Sca-1
2IL-7R
2c-
Kit
+CD34
+FccRII/III
hi, and the megakaryocyte-erythroid pro-
genitors (MEPs) as Lin
2Sca-1
2IL-7R
2c-Kit
+CD34
2FccRII/III
lo.
All analyses were performed on a FACSCanto (BD Biosciences).
Data were processed with the FlowJo software (TreeStar Inc).
Myeloid progenitors (CMPs and GMPs) were sorted on the FACS
Aria (BD Biosciences).
Histomorphometric analysis
The right femur metaphysis was processed for histomorpho-
metric analysis. The proximal halves of femur were fixed in 10%
phosphate-buffered formaldehyde, dehydrated in methanol and
embedded in methylmetacrylate resin without decalcification.
Undecalcified 5-mm-thick longitudinal sections were prepared
using a Leica 2055 microtome (Leica, Rueil-Malmaison, France)
equipped with a tungsten carbide blade. Sections were stained
with Goldner-Masson stain and histomorphometric indices were
measured under blind conditions using a Leitz Aristoplan
microscope (Leica) connected to a Sony DXC-930P color video
camera. An automatic image analyzer (Microvisions Instruments,
Evry, France) was used for bone parameter measurements. The
trabecular bone volume (BV/TV), trabecular thickness (Tb.Th),
trabecular number (Tb.N), trabecular separation (Tb.Sp) and
osteoblast surface (ObS/BS) were measured in the secondary
metaphyseal area of the proximal end of the femur in a
standardized zone located at 300–500 mm from the growth
cartilage and 150–200 mm from the cortices. The cortical
thickness was measured at midshaft diaphysis. The left femurs
were fixed in 4% paraformaldehyde, decalcified with 5% EDTA
for 1 week and embedded in paraffin. Five-mm thick sections were
dewaxed and processed for TRAP staining by incubation for
30 mn at 37uC in substrate solutions containing naphthol AS B1
phosphate (20 mg, Sigma), sodium tartrate (460 mg), fast red
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buffer (pH 5.0). Sections were then rinsed under running tap
water for 5 min, counterstained with fast green dye and mounted
in coverquick. The surface of TRAP-stained cells was measured
for the Oc.S/BS calculation using automatic image analyzer
(Microvisions Instruments, Evry, France).
Homing and lodging assays
Total BM cells were isolated from donor animals (ERK1
2/2 or
WT). Cells were labeled with the cytoplasmic dye carboxyfluor-
escein diacetate succinimidyl diester (CFSE) according to manu-
facturer’s instructions (Molecular Probes, Eugene, OR). In homing
assays, lethally irradiated C57BL/6 mice were injected with
15610
6 ERK1
2/2 or WT CFSE–stained cells. Three and
24 hours after injection, the percentage of CFSE
+ cells in BM
was scored by flow cytometry. In lodging assays, 15610
6 CFSE-
labeled BM cells were transplanted into non irradiated mice.
Three and 24 hours after injection, the percentage of CFSE
+ cells
in recipient-derived BM cells was scored by flow cytometry. The
frequency of CFSE
+ donor cells was determined as previously
described [34].
Limiting dilution competitive bone marrow
transplantation (BMT) assay
For each BMT experiment, 50, 100 or 250 LSK
CD150
+CD48
2 cells of each genotype were mixed with 25610
4
CD45.1/CD45.2 competitors, and subsequently transplanted into
lethally (9,5 Gy) irradiated recipient mice CD45.1. Peripheral
blood in recipient mice was analyzed for the engraftment level of
donor cells at 4 and 20 weeks after BM transplantation. Peripheral
blood was obtained by retro-orbital punction and blood leukocytes
were obtained after hypotonic lysis. Multilineage hematopoietic
engraftement was analyzed with FITC-conjugated CD45.1, APC-
conjugated CD45.2 and the lineage markers Mac1 (CD11b), B220
and CD4 conjugated to (PE). All antibodies are from BioLegend.
Data were analyzed with the FlowJo software (TreeStar Inc). Mice
with over 1% donor descent-cells in the peripheral blood were
counted as ‘‘positive reconstitution’’. CRU frequencies were
calculated using L-Calc software (StemCell Technologies). The
data are pooled from 3 independent experiments.
Serial transplantation in WT and ERK1
2/2 mice
Lethally (9,5 Gy) irradiated 8- to 12-week old ERK1
2/2 and
WT CD45.2 mice were reconstituted with 2000 CD45.1 WT
Lin
2Sca-1
+c-Kit
+ (LSK) injected intravenously into the retro-
orbital plexus in a total volume of 100 mL. Engraftment of
primary recipient mice was analyzed after 20 weeks by flow
cytometric analysis of peripheral blood. To test the self-renewal
activity of the donor HSCs, bone marrow harvested from WT
primary recipients after 20 weeks of engraftment was transplant-
ed into lethally irradiated WT CD45.2 secondary recipients at a
dose of 10
6 cells per mouse. BM harvested from ERK1
2/2
primary recipients was transplanted into lethally irradiated WT
or ERK1
2/2 CD45.2 secondary recipients. Flow cytometric
peripheral blood analysis of the secondary recipients was
performed 20 weeks after transplantation.
In vitro osteoclastogenesis assays
Bone marrow from 8 week-old mice was flushed and
mononuclear cells were purified by centrifugation over lympho-
cyte separation medium (Eurobio, France). Cells were seeded in
24-well plates at 10
5 cells/well in 1 ml of alpha-MEM supple-
mented with 10% FBS, 25 ng/ml M-CSF, and 35 ng/ml
recombinant RANKL (produced at SFR Biosciences UMS344/
US8, PAP facility) [35]. The cultures were maintained for 5 days
and re-fed every 2 days. Osteoclasts were identified by staining for
TRAP activity, using the leukocyte acid phosphatase kit (Sigma
Diagnostics, St. Louis, MO). TRAP-positive multinucleated cells
with greater than three nuclei were counted as osteoclasts. RNA
was isolated from the cells at day 5 of differentiation with cytokines
to measure the expression of osteoclast-associated genes. To assess
the osteoclast in vitro functionality, bone marrow-derived cells were
differentiated in vitro for 4 days, and osteoclasts detached by
treatment with 0,02% EDTA in PBS and numbered. For
resorption test, the same number of osteoclasts from each set
were lifted and seeded onto 24-well Osteo Assay dishes (Corning)
for an additional 24 h. OsteoAssay wells were subsequently stained
with silver nitrate [36]. The surface area was measured with
ImageJ software, using an ImageJ plug-in developed by our
imaging facility (Platim SFR Biosciences)
Deoxypyridinoline cross-link assays
Bone related degradation products from type 1 collagen,
deoxypyridinoline (DPD) cross-links and creatinin were measured
in evening urine using the Pyrilinks-D immunoassay and creatinin
kit (Quidel Corporation, San Diego, CA), according to the
manufacturer’s protocols.
Monocyte/macrophage progenitors proliferation
L929-cell conditioned medium (LCCM) was used as a source of
macrophage colony stimulating factor (M-CSF). Briefly, BM cells
were separated by centrifugation over a Ficoll gradient and further
purified by immunomagnetic depletion of CD45R- (B220),
Ter119-, and CD3e-positive cells. Enriched-mouse bone marrow
monocytes were grown in DMEM-HG supplemented with 20%
fetal calf serum, 30% LCCM, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine, and incubated at 37uCi na
5% CO2 atmosphere. Cell proliferation was evaluated at days 1, 3,
and 7, using Uptiblue viable cell counting reagent (Interchim).
In vitro phagocytic activity assay
Bone marrow-derived macrophages were cultured from WT
and ERK1
2/2 mice. Briefly, marrow was flushed from excised
femur and cultured at 37uC in complete medium (DMEM
supplemented with 20% FBS, 1% L-glutamine, 100 U/ml
penicillin/streptomycin, and 30% LCCM). After 5 days of
differentiation, the cells were scraped, and reseeded in 12-well
plates at 2610
5cells/well. For latex bead uptake assay, green-
yellow fluorescent latex beads (Molecular probes) were diluted
1:300 with complete culture medium and incubated for 30 min-
utes at 37uC. Non-adherent latex beads were removed by vigorous
washing. Cells were then harvested by treatment with 5 mM
EDTA and scraping. The amount of phagocytozed beads was
measured by flow cytometry on F4/80+-gated population. The
amount of nonspecifically bound beads was determined by
incubating macrophages with fluorescent beads on ice. The
experiment was done with macrophages cultured from 3 mice for
each genotype.
RNA extraction and quantitative real-time PCR (qPCR)
Total RNA was isolated from the various samples using RNeasy
mini kit with on-column genomic DNA digestion on column step
according to the manufacturer’s instructions (Qiagen, Valencia,
CA). RNA was then reverse transcribed with random hexamer
primers using Superscript II (Invitrogen). qPCR was performed
with SYBR Green PCR Master mix on a lightcycler (Roche
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30788Figure 1. ERK1 loss alters the bone architecture. Cortical and trabecular parameters in WT and ERK1
2/2 mice (n=5 for each group). (A)
midshaft diaphysis cortical thickness, (B) bone volume/tissue volume (% BV/TV), (C) trabecular thickness (Tb.Th), (D) trabecular number (Tb.N), (E)
trabecular separation (Tb.S). The non parametric Mann-Whiney test was used to calculate the P value. Horizontal bars show the mean values.
doi:10.1371/journal.pone.0030788.g001
Figure 2. ERK1
2/2 microenvironment alters the lodging and the homing efficiencies of BM cells. Lodging of the bone marrow cells into a
non irradiated host were quantified 3 h (A) and 24 h (B) after injection. Homing of the bone marrow cells into a lethally irradiated host were
quantified 3 h (C) and 24 h (D) after injection. Results are presented as scatter plots showing the percentage of recovered CFSE
+ cells in the BM 3 and
24 hours after transplantation. The non parametric Mann-Whiney test was used to calculate the P value. Horizontal bars show the mean values.
doi:10.1371/journal.pone.0030788.g002
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used in these qPCR experiments are listed in Table S1. Data were
analyzed using the DD–Ct relative quantification with each
duplicate sample normalized to actin.
Statistical analysis
All experimental data were analyzed and compared for
statistically significant differences by two-tailed Student’s t test or
the non parametric Mann-Whitney test, as indicated. Data are
presented as the averaged values 6 standard error of the mean
(SEM). All P values reported are of comparisons made to results
obtained with WT animals. The following values were considered
significant: *, P,0.05, **, P,0.01, and ***, P,0.001.
Results
ERK1 deletion increases bone density in vivo
Abnormal bone formation was observed in the ERK1
2/2 mice.
Histomorphometric measurements of WT and ERK1
2/2 mice
femurs were applied to analyze the trabecular and cortical
microarchitecture. Data indicated that the cortical bone mass of
ERK1
2/2 mice showed a significant increase (Figure 1A). The
trabecular bone volume/tissue volume (BV/TV) increased in
ERK1
2/2 mice, though the significance was not reached
(Figure 1B). Likewise not statistically significant, the analysis of
the main trabecular parameters, including trabecular thickness
(Tb.Th, Figure 1C), trabecular number (Tb.N, Figure 1D), and
Figure 3. ERK1
2/2 microenvironment induces a defect in WT HSC activity. (A) Scheme of transplantation assay. (B) Analysis of WT donor
cells engraftment in WT (n=10) and ERK1
2/2 mice (n=10) primary recipient 24 weeks after transplantation. (C) Analysis of WT donor cells
engraftment in WT (n=9 per group) and ERK1
2/2 mice (n=16) secondary recipient 24 weeks after transplantation. In panels B and C, total donor cells
are shown as a percentage of live cells. Individual lineages are shown as a percentage of donor-derived cells. Data represent the mean6SEM, the t-
test was used to calculate the P value.
doi:10.1371/journal.pone.0030788.g003
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between WT and KO animals in accordance to the increased
BV/TV. Though significance was not reached, this finding
suggests that bone-remodeling processes are impaired in
ERK1
2/2 mice.
Bone marrow lodging and homing are altered in the
absence of ERK1
An abnormal bone formation may have a major impact on the
BM microenvironment and, consequently on the lodging and
homing abilities of HSCs. In order to study these properties, WT
and ERK1
2/2 BM cells were labelled with CFSE before being
transplanted into lethally irradiated (homing) or not irradiated
(lodging) WT or ERK1
2/2 recipients. 15610
6 BM labelled-cells
were injected in non-irradiated recipient mice. WT and ERK1
2/2
BM cells were found to lodge similarly in WT recipient mice at
3 hours (Figure 2A) or 24 hours (Figure 2B). However WT and
ERK1
2/2 BM cells both presented a striking defect in their ability
to lodge in ERK1
2/2 recipient mice after 3 and 24 hours
(Figure 2A and B, respectively). Similarly, a defect in homing of
WT and ERK1
2/2 BM cells in ERK1
2/2 mice at 3 hours was
also observed (Figure 2C) which was not longer seen after 24 hours
(Figure 2D). These results indicate that the lodging and the
homing abilities of the ERK1
2/2 HSC are impaired.
The hematopoietic bone marrow microenvironment is
defective in the absence of ERK1
The ERK1
2/2-defective environment may affect the engraf-
ment of HSCs in competitive repopulation assays. Lethally
irradiated 8- to 12 week-old ERK1 mutant and littermate control
mice (both CD45.2 genotype) were transplanted with 2 000
Lin
2Sca1
+c-kit
+ (LSK) isolated from wild-type CD45.1 mice
(Figure 3A). Long term and multilineage engraftment of primary
recipients was confirmed by flow cytometry analysis of peripheral
blood (Figure 3B). WT donor cells that had been transplanted in
ERK1
2/2 recipients reconstituted hematopoiesis to a lesser
extent, even though this was not statistically significant
(Figure 3B). In order to test the self-renewal activity of the donor
HSCs, BM harvested from WT and ERK1
2/2 primary recipients
after four months of engraftment was transplanted into lethally
irradiated WT or ERK1
2/2 secondary recipients at a dose of 10
6
cells per mouse (Figure 3A). Flow cytometric analysis of PB of the
secondary recipients 4 months after transplantation revealed that
WT donor cells passaged through a primary mutant microenvi-
ronment reconstituted hematopoiesis to a much lower extent when
transplanted in a ERK1
2/2 second recipient (2.9-fold decreased,
P=0.0005), compared with WT cells passaged through a primary
mutant microenvironment and then transplantated in a secondary
WT recipient (Figure 3C). These data strongly support the
hypothesis that ERK1 is involved in the maintenance of an
appropriate medullar microenvironment, but that the intrinsic
properties of HSCs are not altered by the ERK1
2/2 defective
microenvironment. In agreement with that, the frequency of
functional ERK1
2/2 HSCs (CRU) is identical to that of WT
HSCs when tested in limiting dilution conditions (Table S2).
Development and maturation of osteoclasts are impaired
in the absence of ERK1. Among the cells involved in these
specialized microenvironments, osteoclasts and osteoblasts play
Figure 4. Deletion of ERK1 impairs osteoclast formation without any effects on osteoblasts. WT and ERK1
2/2 mouse femur sections were
stained with Trichrome Goldner-Masson stain (A) and revealed for TRAP activity (B). Ob.S/BS and Oc.S/BS parameters were calculated from Goldner
trichrome and TRAP activity sections, respectively. Data are the means6S.E.M. (n =5 per group). Data represent the mean6SEM, the Mann-Whitney
test was used to calculate the P value.
doi:10.1371/journal.pone.0030788.g004
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between bone-forming osteoblasts (OBs), and bone-resorbing
osteoclasts (OCs). To address whether the bone phenotype
observed in ERK1
2/2 mice is a consequence of a deregulation
of the balance between OBs and OCs, these cells were quantified
on bone sections. No difference in OB number between WT and
ERK1
2/2 animals was observed (Figure 4A). Furthermore, the
expression of osteoblast-associated genes was similar between the
two genotypes (Figure S1). These data suggest that OBs were not
altered in ERK1
2/2 mice. We next determined if increased bone
in ERK1
2/2 mice is a consequence of impaired bone resorption.
TRAP staining of bone sections demonstrated a significant
increase in the numbers of ERK1
2/2 TRAP+ cells along the
trabecular endosteum, in comparison to their WT counterparts
(Figure 4B). To evaluate if ERK1 deletion leads to impaired OC
function, we tested the differentiation potential of ERK1
2/2 and
WT BMMCs cultured with M-CSF and RANKL. Following 5
days of differentiation, TRAP staining of WT and ERK1
2/2
osteoclasts grown in vitro revealed a dramatic impairment of
osteoclastogenesis in KO cultures with a reduction of osteoclast
number by almost 2 fold (Figure 5A). In addition, these ERK1
2/2
osteoclasts appeared smaller, with a reduced ability to form
multinucleated cells (Figure 5B). Transcriptional assessment of the
osteoclast-associated genes RANK and cathepsin K (CTSK), after
5 days in culture under osteoclastogenic conditions, revealed that
ERK1
2/2 BM cells exhibited significant reduced expression of
these markers of terminal osteoclastic differentiation, while the
mRNAlevelsofthe calcitoninreceptor (CaR)showedonlya modest
decrease (Figure 5C). Osteoclast activity was further assessed by
analyzing dentin resorption pits after 6 days of culture.
Quantification of the resorption areas, normalized to the numbers
of osteoclasts, revealed a drastic reduction (,85%) in the resorptive
capacity of ERK1
2/2 osteoclasts as compared to their wild-type
counterparts (Figures 5D–E). To address the functionality of OCs in
vivo, we measured the urinary deoxypyridinoline (DPD)
concentration. DPD is the product of the degradation of type I
collagen and is a read-out of the ongoing bone resorption process.
Urinary excretion of DPD was lower in ERK1
2/2 mice compared
to WT (6.7260.27 vs 5.5260.58 nmol/mmol creatinine, P=0.06,
n=8 for each genotype). These results suggest that ERK1 is
required for the regulation of normal osteoclast development.
ERK1 loss alters bone marrow monocyte frequency in
vivo and monocytes progenitors proliferation in vitro
As osteoclasts derive from precursors of the monocyte/
macrophage lineage, investigation of the monocytic compartment
was performed to fully characterize the ERK1 cellular target.
Monocytes originate in the bone marrow in a CD115 (M-CSFR)-
dependent manner from a myeloid progenitor [37]. We therefore
used Gr1 and CD115 antibodies to identify BM monocytes by
flow cytometry [38]. Results showed a significant reduction of the
frequency of Gr1
+/CD115
+ monocytes in ERK1
2/2 mice
Figure 5. ERK1 deficiency impairs osteoclastogenesis. (A) Total number of osteoclasts per well following 5 days of culture under
osteoclastogenic condition (n=3) (B) Representative picture of TRAP-positive multinucleated osteoclasts generated from BMNCs of WT and ERK1
2/2
mice. (C) Relative expression of cathepsin K (CTSK), calcitonin receptor (CaR), and receptor activator of nuclear factor kappa B (RANK) in WT and
ERK1
2/2 osteoclasts. (D) Representative pictures of the bone resorption pits formed by WT and ERK1
2/2 derived osteoclasts. (E) Bar graph
representing the quantification of the resorptive area per dentin slice for WT and ERK1
2/2 osteoclasts (n=3). Data represent the mean6 SEM. The t-
test was used to calculate the P value.
doi:10.1371/journal.pone.0030788.g005
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(MFI) of CD115 was also reduced, indicating that the overall
expression of the receptor in this population is decreased
(36746317 for WT vs 32446234 for ERK1
2/2). We next
investigated if the reduced number of monocytes in the BM may
be a consequence of an altered proliferation of monocyte
progenitors. BM mononuclear-enriched myeloid cells isolated
from WT and ERK1
2/2 mice were grown in L929-conditioned
medium for up to 7 days and tested for their proliferation ability.
The results obtained showed that deletion of ERK1 delayed M-
CSF-induced monocytes progenitors proliferation (Figure S2).
These overall data suggest that ERK1 contribute to the regulation
of monocytes progenitors proliferation through the activation of
the M-CSF signaling.
ERK1 deletion does not affect macrophage
differentiation and functionality
We further investigated if the alteration of the response to M-
CSF in vitro was correlated with a decrease of mature macrophages
number in vivo. The splenic macrophages have been characterized
as F4/80
hiCD11b
lo/2 cells with strong autofluorescence [39,40].
The WT and the ERK1
2/2 spleen cells were stained with
antibodies to F4/80 and CD11b.The results obtained showed no
difference between the ERK1
2/2 and WT mice (1.18%60.09%
for WT and 1.25%60.21% for ERK1
2/2,P=0.36, n=6 for both
groups). Recently, bone marrow resident macrophages have been
described based on differential expression of Gr1, CD115, and
F4/80 [38]. According to this labeling, BM macrophages were
identified in WT and ERK1
2/2 mice, and showed no significant
difference in their frequency (Figure S3). These data suggest that in
vivo, mechanisms can compensate for the reduction of monocyte/
macrophage progenitors, resulting in a normal distribution of
macrophages in the organs under steady-state conditions. In
particular, granulocyte-macrophage CSF (GM-CSF) and IL-3
contribute to M-CSF-independent recovery for some macrophag-
es populations in M-CSF-deficient mice [19]. We further
investigated the functionality of macrophages from WT and
ERK1
2/2 mice. The phagocytic activity of BM-derived macro-
phages (BMM) was evaluated by measuring the capacity of the
cells to ingest latex beads in vitro. The results showed that
phagocytosis efficiency was similar in WT and ERK1
2/2 BMM
(Figure S4).
ERK1 deletion alters the myeloid progenitors
compartment
In vivo analysis of the myeloid lineage progenitors, CMP, GMP
and MEP subsets revealed a significant phenotypical change in the
CMP and GMP subsets in the ERK1
2/2 mice (Figure 7A). The
frequency of CMPs increased by approximately 1.3-fold, while the
frequency of GMPs significantly decreased by almost 2-fold,
compared with the respective WT compartments (Figure 7A, B).
In parallel, the frequency of MEPs showed no change between
WT and ERK1
2/2 mice. These data suggest that ERK1 deletion
alters the differentiation of CMPs into GMPs, while it does not
affect the MEP commitment and that the CMPs are the cellular
targets of ERK1. We have previously shown that ERK1 loss
impairs both the osteoclasts and the bone marrow monocytes. As
these cells originate in the bone marrow in a CD115 (M-CSFR)-
dependent manner from a myeloid progenitor, we next quantified
the expression of CD115 in the GMP and CMP subsets. We
observed a 2-fold reduction of the GMPs expressing CD115
(14.1%63% and 6.96%62.8% for WT and ERK1
2/2 mice,
respectively, P=0.04; n=3). Furthermore, the mean fluorescence
intensity of CD115 was lower in ERK1
2/2 GMPs compared to
WT (MFI: 21616190 vs 25506119; P=0.04; n=3). When gated
on the CMP subset, the fraction of CD115-positive cells was too
low for interpretation. To get insight in the regulation of CD115
expression in myeloid progenitors, we next measured the
expression of CD115 mRNA in WT and ERK1
2/2 GMP-sorted
populations. The mRNA expression of CD115 was found to be
similar in WT and ERK1
2/2. No difference in the level of CD115
mRNA was found between WT and ERK1
2/2 GMP nor CMP,
though the level of CD115 gene expression is very low in these
latter cells (Figure S5). These results show that the cellular targets
of ERK1 are M-CSFR-responsive cells, upstream to osteoclasts.
Discussion
In this study we aimed to decipher the role of ERK1 in vivo in
the regulation of HSCs. We show that ERK1
2/2 mice exhibit an
overall increase in bone density. These skeletal abnormalities are
caused by a deficiency of the osteoclast function. In agreement
with these data, mice deficient for ERK1 develop a mild
osteopetrosis. Our results provide evidence that ERK1 is involved
in the maintenance of an appropriate medullar microenvironment
and plays a role in the cells that comprise the hematopoietic
microenvironment.
Our results indicate that ERK1 deletion causes defective
lodging and homing. This defect results in impaired capacity of
WT cells to reconstitute when serially transplanted in ERK1
2/2
mice. This lower capacity was more pronounced when WT donor
cells passaged through a primary mutant microenvironment were
transplanted in a ERK1
2/2 second recipient mice. This result
reveals that the negative impact on hematopoietic recovery is
Figure 6. ERK1
2/2 mice have a reduced fraction of bone
marrow monocytes. (A) Representative FACS plot of BM monocytes
defined as Gr1
+CD115
+ cells. (B) Proportion of monocytes as described
above in the total BM in WT (n=11) and ERK1
2/2 (n=12). Data
represent the mean6SEM. The t-test was used to calculate the P value.
doi:10.1371/journal.pone.0030788.g006
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contrast, the deletion of ERK1 was without effect on the functional
properties of HSCs. An altered BM niche could explain the
defective effects observed. Specifically, ERK1 may be necessary in
cell types implicated in the regulation of the niche size. Previous
studies have introduced the link between bone remodeling and the
regulation of hematopoiesis, suggesting a dynamic nature of the
BM stem cell niche [7]. Among the cellular components of the
medullar niches, osteoclasts are have been shown to be involved in
the hematopoietic niche homeostasis [41,42], controlling both the
maintenance and the release of HSC. In the ERK1
2/2 mice, the
major default of in vitro osteoclastogenesis contrasts with the in vivo
increased number of osteoclasts. This could be due to an increased
production of osteoclasts to compensate their functional defect.
Indeed, similar processes of regulation have been previously
described in other osteoclast-defective models [43,44,45]. While
this paper was in preparation, Y. He et al. also reported a major
defect of bone resorbing activity in ERK1
2/2 mice [33].
However, they showed that in addition to both in vitro and in vivo
bone-resorbing activity alterations, the number of osteoclasts was
markedly reduced in ERK1
2/2 trabecular area. Variations
between these results and ours may reflect differences in the
conditions of animal housing and/or ERK1
2/2 mouse line
maintenance, resulting in phenotypes with various degrees of
severity. However, although the osteopetrotic phenotype described
by He and colleagues was more severe than that we observed, the
cellular mechanisms underlying this default are the same.
In addition to the defect in osteoclastogenesis, we report an
overall compromised mononuclear-phagocyte lineage develop-
ment in ERK1
2/2 mice, through the alteration of M-CSFR
expression. Mice defective for M-CSFR (Csf1r
2/Csf1r
2)mice are
severely osteopetrotic, with reduced mononuclear phagocyte
production, reduced number of macrophages, and development
of a splenomegaly [9]. We found similar characteristics in our
model, but with a less severe phenotype. This corroborates the
reduced expression of M-CSFR
+ cells in ERK1
2/2 mice. It is
well-known that ERK is a downstream effector of M-CSFR and
that it contributes to the regulation of myelopoiesis. However, it is
to our knowledge, the first demonstration of a control of M-CSFR
expression downstream of ERK1. The loss of ERK1 leads to
impaired expression of the M-CSFR in myeloid progenitors and
induce a delay in their differentiation program, as shown by the
accumulation of CMPs in ERK1
2/2 bone marrow, while the
proportion of GMPs was reduced. The fraction of CD115-positive
cells on the CMP subset was too low for interpretation. The CMPs
have been shown to be divided into three phenotypically,
functionally and developmentally distinct cell subsets [46] that
express or not the M-CSFR. In our study we quantified the M-
CSFR expression on the overall CMP population. The M-CSFR
expression study in the three described subsets in the ERK1
2/2
Figure 7. ERK1 deficiency alters the myeloid lineage differentiation. (A) Representative FACS plot of CMP, GMP, and MEP in WT and ERK1
2/2
mice. (B) Frequency of CMP, GMP, and MEP populations in WT and ERK1
2/2 mice calculated according to the gating strategy shown in panel A.
Values are derived from 6 mice of each genotype. Data represent the mean6SEM. The t-test was used to calculate the P value.
doi:10.1371/journal.pone.0030788.g007
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increase of the CMP compartment. Furthermore, we reported a
decrease in the BM monocytic population (Gr1
+/CD115
+)i n
ERK1
2/2 mice. Together, these data suggest that ERK1 plays a
key role in myelopoiesis by controlling the expression of M-CSFR.
This control does not take place at the transcriptional level, as the
expression of the M-CSFR mRNA is not different between WT
and ERK1
2/2, in neither GMP or CMP myeloid progenitors.
This means that receptor synthesis is more likely to be governed by
posttranscriptional regulation as previously suggested [47]. Thus,
we can hypothesize that ERK1 is involved in the posttranscrip-
tional mechanisms regulating the expression of the M-CSFR. In
line with this hypothesis, it has been shown that the ERK pathway
is involved in the mechanisms that control M-CSFR turnover [48].
In summary, our results show that the microenvironmental
default observed in ERK1
2/2 mice is in fact a consequence of an
erroneous myeloid lineage commitment. It has been recently
published that the inhibitor of differentiation (Id1) gene plays a
role in regulation of bone and BM physiology [20]. In Id1
2/2
mice, the osteoporosis phenotype and increased osteoclasts
observed are suggested to be due to a decrease of the CMP
population. Likewise, our study suggests that GMPs/CMPs are the
ERK1 potential cellular targets. The ERK1-regulated M-CSFR
expression characterizes one of the mechanisms involved. While
ERK1 is well known to be activated by M-CSF, the present results
are the first to point out an ERK1-dependent M-CSFR regulation
on hematopoietic progenitors. The observed bone and BM
microenvironment phenotypes as well as the decreased osteoclas-
togenesis in ERK1
2/2 mice are due to an altered homeostasis of
the myeloid precursors cells. This study reinforces the hypothesis
of an active cross-talk between HSCs, their progeny and bone cells
in the maintenance of the homeostasis of these compartments.
Supporting Information
Figure S1 qPCR analysis of the osteoblast-associated
genes RUNX2, alkaline phosphatase (ALP), osteocalcin
(OSC), osteopontin (OPN) in WT and ERK1
2/2 bone
samples. Data are presented as the mean 6 SEM, n=3 for each
genotype.
(TIF)
Figure S2 M-CSF induced proliferation of BM mono-
cyte/macrophage progenitors. Enriched monocyte/macro-
phage progenitors were grown in vitro in L929-conditioned
medium for up to 7 days. Cell proliferation was monitored by
means of the fluorimetric metabolic growth indicator Uptiblue
(Interchim) at the indicated days. Data show that deletion of
ERK1 induces a delay in growth of cells during the first days of
culture.
(TIF)
Figure S3 Gating strategy for the BM macrophages.
Gated on the Gr1
2 population, F4/80
+CD115
2 cells were further
subdivided on a FSC/SSC plot. SSC
int/lo cells are considered as
macrophages. Results are representative of 3 independent
experiments, for a total of 9 mice for each genotype.
(TIF)
Figure S4 Bead incorporation of BM-derived macro-
phages. BM-derived macrophages were incubated for 30 min-
utes with fluorescent latex beads at 37uC. Cells were then
detached, and the fluorescence distribution was evaluated by
FACS on F4/80
+ gated population. No difference was seen
between WT and ERK1
2/2 macrophages. The histograms
represent the percentage of macrophages that incorporated the
indicated number of beads (n=3 mice for each genotype).
(TIF)
Figure S5 qPCR analysis of M-CSFR gene expression in
WT and ERK1
2/2 CMPs and GMPs. Data are presented as
the mean 6 SEM, n=5 for each genotype.
(TIF)
Table S1 Primer sequence list.
(TIF)
Table S2 CRU frequencies of WT and ERK1
2/2 HSCs.
(TIF)
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